MA50488A - Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique - Google Patents

Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Info

Publication number
MA50488A
MA50488A MA050488A MA50488A MA50488A MA 50488 A MA50488 A MA 50488A MA 050488 A MA050488 A MA 050488A MA 50488 A MA50488 A MA 50488A MA 50488 A MA50488 A MA 50488A
Authority
MA
Morocco
Prior art keywords
anticholinergic
corticosteroid
adrenergic
beta
preparing
Prior art date
Application number
MA050488A
Other languages
English (en)
Other versions
MA50488B1 (fr
Inventor
Claudio Cafiero
Leonardo Ortenzi
Francesca Schiaretti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50488(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA50488A publication Critical patent/MA50488A/fr
Publication of MA50488B1 publication Critical patent/MA50488B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
MA50488A 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique MA50488B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194660 2015-11-16

Publications (2)

Publication Number Publication Date
MA50488A true MA50488A (fr) 2021-05-19
MA50488B1 MA50488B1 (fr) 2021-09-30

Family

ID=54548062

Family Applications (3)

Application Number Title Priority Date Filing Date
MA50487A MA50487B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA43256A MA43256B1 (fr) 2015-11-16 2016-11-14 Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA50488A MA50488B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA50487A MA50487B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA43256A MA43256B1 (fr) 2015-11-16 2016-11-14 Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Country Status (36)

Country Link
US (4) US10086004B2 (fr)
EP (3) EP3377108B1 (fr)
JP (1) JP6963548B2 (fr)
KR (1) KR20180082443A (fr)
CN (1) CN108289962B (fr)
AR (1) AR106688A1 (fr)
AU (1) AU2016356858B2 (fr)
CA (1) CA3005290A1 (fr)
CL (1) CL2018001298A1 (fr)
CO (1) CO2018005141A2 (fr)
CY (3) CY1123042T1 (fr)
DK (3) DK3628331T3 (fr)
EA (1) EA037716B1 (fr)
ES (3) ES2891073T3 (fr)
GE (1) GEP20207157B (fr)
HR (3) HRP20211598T1 (fr)
HU (3) HUE056260T2 (fr)
IL (1) IL259329B (fr)
LT (3) LT3377108T (fr)
MA (3) MA50487B1 (fr)
MD (3) MD3377108T2 (fr)
ME (1) ME03778B (fr)
MX (1) MX379853B (fr)
MY (1) MY186229A (fr)
PE (1) PE20181488A1 (fr)
PH (1) PH12018501022A1 (fr)
PL (3) PL3377108T3 (fr)
PT (3) PT3620176T (fr)
RS (3) RS62404B1 (fr)
SA (1) SA518391570B1 (fr)
SG (2) SG10201912093YA (fr)
SI (3) SI3620176T1 (fr)
TW (1) TWI731891B (fr)
UA (1) UA125019C2 (fr)
WO (1) WO2017085004A1 (fr)
ZA (1) ZA201803168B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582269B (zh) * 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
KR20220155609A (ko) 2017-05-11 2022-11-23 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
EP3947338A4 (fr) * 2019-03-27 2023-01-04 Kemin Industries, Inc. Procédés de préparation de carboxylates métalliques dans une réaction monotope
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
WO2022045995A1 (fr) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé de préparation de compositions de poudre sèche pour inhalation
US12178782B2 (en) * 2021-03-24 2024-12-31 Cmpd Licensing, Llc Drug powderization within vials
WO2023117967A1 (fr) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Formulations en poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
DE60239639D1 (de) 2002-07-31 2011-05-12 Chiesi Farma Spa Pulverinhalator
CA2785321C (fr) * 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Polytherapie pour bronchopneumopathie chronique obstructive (copd)
CN102946868B (zh) * 2010-06-22 2014-10-29 奇斯药制品公司 包含抗毒蕈碱药的干粉制剂
AR093832A1 (es) * 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
HUE051394T2 (hu) * 2012-12-06 2021-03-01 Chiesi Farm Spa Muszkarin receptor antagonista és béta2 adrenerg receptor agonista aktivitással rendelkezõ vegyületek
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PT3019153T (pt) 2013-07-11 2018-12-04 Chiesi Farm Spa Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação

Also Published As

Publication number Publication date
PE20181488A1 (es) 2018-09-18
SG10201912093YA (en) 2020-02-27
SG11201804050QA (en) 2018-06-28
AR106688A1 (es) 2018-02-07
HUE049751T2 (hu) 2020-10-28
CY1124490T1 (el) 2022-07-22
EP3377108A1 (fr) 2018-09-26
BR112018009807A8 (pt) 2019-02-26
EP3628331A1 (fr) 2020-04-01
EA037716B1 (ru) 2021-05-13
DK3620176T3 (da) 2021-09-20
SI3628331T1 (sl) 2021-11-30
AU2016356858B2 (en) 2021-06-24
EA201890966A1 (ru) 2018-11-30
MA50488B1 (fr) 2021-09-30
PL3377108T3 (pl) 2020-09-07
LT3620176T (lt) 2021-11-10
MD3620176T2 (ro) 2021-12-31
NZ742474A (en) 2024-11-29
ME03778B (fr) 2021-04-20
US20170136035A1 (en) 2017-05-18
MA43256B1 (fr) 2020-05-29
MX2018005977A (es) 2018-08-29
SI3377108T1 (sl) 2020-05-29
US20200368252A1 (en) 2020-11-26
US20210177866A1 (en) 2021-06-17
US10086004B2 (en) 2018-10-02
US20180360849A1 (en) 2018-12-20
HRP20211600T1 (hr) 2022-01-21
DK3377108T3 (da) 2020-04-20
CO2018005141A2 (es) 2018-09-28
RS62506B1 (sr) 2021-11-30
EP3620176B1 (fr) 2021-08-11
US11628175B2 (en) 2023-04-18
IL259329B (en) 2020-10-29
LT3628331T (lt) 2021-11-10
HUE056441T2 (hu) 2022-02-28
CA3005290A1 (fr) 2017-05-26
IL259329A (en) 2018-07-31
MA43256A (fr) 2018-09-26
MY186229A (en) 2021-06-30
CY1123042T1 (el) 2021-10-29
LT3377108T (lt) 2020-07-10
RS60171B1 (sr) 2020-05-29
PT3377108T (pt) 2020-04-08
CN108289962A (zh) 2018-07-17
PL3620176T3 (pl) 2021-11-22
ES2895687T3 (es) 2022-02-22
TW201722404A (zh) 2017-07-01
SI3620176T1 (sl) 2021-11-30
JP2019501876A (ja) 2019-01-24
ZA201803168B (en) 2019-07-31
MA50487A (fr) 2021-04-28
MD3628331T2 (ro) 2021-12-31
PL3628331T3 (pl) 2021-11-08
BR112018009807A2 (pt) 2018-11-06
HRP20200537T1 (hr) 2020-06-26
TWI731891B (zh) 2021-07-01
EP3628331B1 (fr) 2021-08-11
CL2018001298A1 (es) 2018-09-14
GEP20207157B (en) 2020-10-12
US10772896B2 (en) 2020-09-15
KR20180082443A (ko) 2018-07-18
EP3620176A1 (fr) 2020-03-11
MX379853B (es) 2025-03-11
DK3628331T3 (da) 2021-09-27
ES2891073T3 (es) 2022-01-26
WO2017085004A1 (fr) 2017-05-26
EP3377108B1 (fr) 2020-02-19
UA125019C2 (uk) 2021-12-29
HUE056260T2 (hu) 2022-02-28
MA50487B1 (fr) 2021-09-30
PT3620176T (pt) 2021-09-28
SA518391570B1 (ar) 2022-03-27
MD3377108T2 (ro) 2020-07-31
PH12018501022B1 (en) 2018-12-17
PH12018501022A1 (en) 2018-12-17
AU2016356858A1 (en) 2018-05-31
US10966991B2 (en) 2021-04-06
ES2783855T3 (es) 2020-09-18
RS62404B1 (sr) 2021-10-29
CY1124475T1 (el) 2022-07-22
JP6963548B2 (ja) 2021-11-10
HRP20211598T1 (hr) 2022-01-07
CN108289962B (zh) 2021-09-14
PT3628331T (pt) 2021-10-20

Similar Documents

Publication Publication Date Title
ME03778B (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
EP3453707A4 (fr) Dérivé de benzazépine, procédé pour le préparer, composition pharmaceutique et son utilisation
EP3486242A4 (fr) Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique
MA43242A (fr) Mélange pour traiter des engrais à base d'urée
EP3357491A4 (fr) Composition pharmaceutique contenant un médicament anionique, et son procédé de préparation
EP3406625A4 (fr) Poudre d'oligopeptides de noix, et son procédé de préparation et application associée
PL3224254T3 (pl) Podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków
EP3353841A4 (fr) Procédé de préparation et d'application de composites de carbone-sélénium
EP3349586A4 (fr) Procédé de préparation d'un composé antifongique
MA52252A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
MA52437A (fr) Une formulation de poudre sèche contenant un anticholinergique, un corticoïde et un bêta-adrénergique
EP3438105A4 (fr) Composé de diaryl-b-lactame et son procédé de préparation et utilisation pharmaceutique associée
EP3391875A4 (fr) Procédé de préparation de micelle polymère contenant un médicament anionique
EP3398615A4 (fr) Composition pharmaceutique mucoadhésive et son procédé de préparation
EP3323823A4 (fr) Composé métallocène et procédé de préparation dudit composé
MA42423A (fr) Procédé de préparation d'un revêtement
EP3294310A4 (fr) Composition oléorésineuse en poudre hautement concentrée et procédé de préparation de cette composition
EP3305283A4 (fr) Composition pharmaceutique stabilisée et son procédé de préparation
MA48620A (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA48621A (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
EP3564219A4 (fr) Procédé de préparation d'un composé oxadiazacyclo et son utilisation
EP3313835A4 (fr) Procédé de préparation d'oltipraz
EP3328435A4 (fr) Composition pharmaceutique à stabilité au stockage améliorée, et son procédé de préparation
EP3307717A4 (fr) Nouveau procédé de préparation d'enzalutamide
EP3328436A4 (fr) Composition pharmaceutique à stabilité au stockage améliorée, et son procédé de préparation